TICKER INTELLIGENCE
NYSE/NASDAQ: MRK
13
Active Bills
1
Gov't Contracts
50
Congressional Trades
Merck is a publicly traded company in the Healthcare sector. Operating in the heavily regulated healthcare industry, this company is significantly impacted by Medicare/Medicaid policy changes, FDA regulatory decisions, and pharmaceutical pricing legislation. HillSignal is tracking 14 active Congressional signals mentioning Merck, including 13 bills and 1 federal contract. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
⚠ ⚠️ PRESIDENTIAL ACTION: Presidential Memorandum signed 7/30/2026: "Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended". This DPA action will boost investment and production in domestic critical mineral recycling and processing, likely increasing stock valuations for pure-play recovery companies and defense contractors reliant on secure rare-earth magnet supplies, while potentially raising costs for import-dependent manufacturers.
⚠ Rep. Gottheimer bought $1K-$15K in XOM on Feb 2 and Feb 4, 2026 — about 97-99 days before HR8753 (Gas Tax Relief Act) was introduced on May 12, 2026. The bill would suspend the federal gas tax, potentially boosting oil company margins, though the trades occurred well before the bill's introduction.
⚠ Rep. Gottheimer sold $1,001 - $15,000 in INTU on 2026-02-20 — 6 days before the "Direct File Act of 2026" (S3948) was introduced, which establishes a government-run tax preparation system.
⚠ System: No overlapping signals found
⚠ System: No overlapping signals found
⚠ Rep. Julie Johnson bought $1,001 - $15,000 in RSG on 2025-12-18, 8 days before S216 ("Save Our Seas 2.0 Amendments Act") was enacted, which could create new revenue streams for waste management.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rep. Julie Johnson sold $1,001 - $15,000 in ADBE on November 3, 2025 — 2 days before the AI-Related Job Impacts Clarity Act (S3108) was introduced, a bill potentially increasing compliance burdens for tech companies.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Gilbert Cisneros bought $1,001 - $15,000 in LMT on 2025-08-05, 56 days before the Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026 (HR3838) was enacted, which significantly impacts defense contractors.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Representative Johnson sold $1,001 - $15,000 in APD on 2025-08-14, 20 days before the 'Stop Chinese Fentanyl Act of 2025' (HR747) was introduced. This bill expands sanctions on Chinese entities involved in opioid and precursor production.
⚠ System: No suspicious timing patterns detected
⚠ Marjorie Taylor Greene bought $1,001 - $15,000 in MRK on 2025-08-28, 7 days before HR5127 ("PrEP and PEP are Prevention Act") was introduced, which could increase demand for drugs like those made by Merck.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rep. Franklin sold $15,001-$50,000 in MSFT on 2025-06-16 — 10 days before the STOP CSAM Act of 2025 (S1829) advanced, a bill that could increase regulatory scrutiny on tech companies.
⚠ Rep. Julie Johnson bought $1,001 - $15,000 in MRK on June 13, 2025 — 83 days before the "PrEP and PEP are Prevention Act" (HR5127) was introduced, which mandates no-cost coverage for HIV prevention drugs.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Representative Franklin bought $1,001 - $15,000 in AMGN on 2024-08-07, 245 days before the BRAIN Act (HR2767) was introduced, a bill aiming to increase research for brain tumor treatment.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Michael T. McCaul bought $1,000,001-$5,000,000 in HUM (HUMANA INC) on 2025-05-19, 1 day before S1816 ("Improving Seniors’ Timely Access to Care Act of 2025") was introduced, which mandates electronic prior authorization for Medicare Advantage plans.
⚠ Gilbert Cisneros bought $15,001 - $50,000 in JNJ on 2025-05-30, 6 days before the 'Treat and Reduce Obesity Act of 2025' (S1973) was introduced, which aims to expand Medicare coverage for obesity treatments.
⚠ System: No suspicious timing patterns detected
⚠ Rep. Rob Bresnahan bought $1,001 - $15,000 in CAT on 2025-05-15 — 1 day before Kiewit Infrastructure West Co. was awarded a $218M Department of the Interior Contract.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Michael T. McCaul bought $1,000,001-$5,000,000 in MRK on 2025-04-02 — 7 days before the BRAIN Act (HR2767) was introduced, which aims to increase research for brain tumor treatment.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
HR7391 is an early-stage bill mandating upfront 340B ceiling pricing for FQHCs. It eliminates rebate reconciliation, structurally benefiting PBMs and managed care organizations handling safety-net populations. The bill has 49 cosponsors but remains in committee with no appropriation attached. Modest structural win for Optum Rx ($UNH) but negligible near-term financial impact.
The Protecting Americans from Unsafe Drugs Act of 2026 (HR7980) would expand FDA mandatory recall authority from controlled substances to all drugs, increasing structural operational risk and compliance costs for major pharmaceutical manufacturers. The bill is at an early legislative stage with a single Democratic sponsor, giving it low near-term passage probability. Market data shows the sector is already under pressure in April 2026 with JNJ, PFE, MRK, and AZN all down significantly over 30 days, but this bill is not yet being priced in as a material risk.
→ Manufacturers face increased compliance costs for recall infrastructure and higher potential liability from mandatory recalls.
HR8032 (FAIC Act) is an early-stage bill requiring separate Medicare Part B payment for qualifying cancer drugs, eliminating a hospital incentive to avoid expensive branded oncology therapies. The bill protects $50B+ in oncology drug revenue for major pharma companies but faces a long legislative path through two committees. Current stock prices for affected tickers are near the bottom of their 52-week ranges, suggesting market pessimism is already priced in, creating asymmetric upside if the bill advances.
→ Hospitals lose their current ability to profit from the spread between bundled payment and the drug's acquisition cost; they must now administer qualifying branded cancer drugs and receive separate, pass-through payment at average sales price (ASP) plus a potential adjustment, removing the structural disincentive against using high-cost branded oncology therapies.
HR1492 retroactively extends the Medicare price negotiation safe harbor for small-molecule drugs from 7 to 11 years, matching biologics. This shields billions in revenue for major pharma companies, particularly pure-play small-molecule firms like Vertex and large players with top-selling Part D drugs like Pfizer, Bristol-Myers Squibb, and Gilead. The bill is early-stage with 67 cosponsors and a Republican sponsor, giving it moderate momentum.
→ Merck's top-selling small-molecule drugs (e.g., Januvia, Keytruda has biosimilar competition but small-molecule Janumet, and cancer drugs) are shielded from negotiation for an additional 4 years.
The Lowering Drug Costs for American Families Act (HR6166) expands Medicare drug negotiation from 20 to 50 drugs and extends inflation rebates to commercial markets, targeting bearish revenue compression for major pharma ($MRK, $PFE, $LLY). Health insurers ($UNH, $CVS) face mixed effects — lower drug costs offset by new out-of-pocket caps. The bill is in early committee stage, giving markets time to price in the structural shift.
→ Forces negotiation of maximum fair prices on up to 50 drugs; imposes inflation rebate on commercial payer price increases above inflation.
The EPIC Act of 2025 would extend small-molecule drug exclusivity before Medicare price negotiation from 7 to 11 years for drugs approved after 2028. Despite sector-wide 30-day declines ($MRK -7.18%, $GSK -5.02%, $PFE -4.24%), the bill's early-stage status (referred to Senate Finance Committee) and long legislative path mean no near-term revenue impact. The structural beneficiary is clear: small-molecule-focused pharma pipelines gain 4 additional years of un-negotiated pricing.
→ Small-molecule drugs approved after 2028 will have an additional 4 years of market exclusivity before facing mandatory price negotiation with CMS, delaying potential revenue erosion from government-set prices.
HR6485 (Skinny Labels, Big Savings Act) creates a statutory safe harbor protecting generic and biosimilar manufacturers from patent infringement liability when marketing drugs for non-patented indications, directly reversing the GlaxoSmithKline v. Teva precedent. Generic makers TEVA and VTRS are structural winners, with reduced litigation risk supporting their generic launch strategies. Brand-name manufacturers AMGN, PFE, JNJ, and MRK face accelerated competitive erosion on their top-selling drugs. The bill is early-stage (referred to House Judiciary), but companion Senate bill S43 signals bipartisan interest.
→ Accelerated market entry of generic and biosimilar competitors for branded drugs' non-patented indications, eroding sales volume and pricing power on those uses.
The ABC Safe Drug Act (S. 1407) is in early legislative stages, having been referred to the Senate Finance Committee. It phases in restrictions on federal health programs purchasing drugs with Chinese active ingredients by 2030 and provides temporary tax incentives for domestic pharmaceutical manufacturing. Major pharma stocks ($PFE, $MRK, $JNJ, $LLY, $AMGN) show mixed but broadly negative 7-day changes, reflecting sector headwinds rather than this nascent bill. No market-moving impact is imminent.
→ Merck incurs compliance costs for API sourcing changes or reshoring, but benefits from 100% bonus depreciation on qualifying U.S. manufacturing equipment placed in service through 2030.
HR7837, the Most Favored Patient Act of 2026, is a bearish catalyst for major pharmaceutical companies with high Medicare exposure. The bill proposes linking US Medicare drug prices to the lowest global price, directly threatening the US pricing premium that supports current industry margins. The bill is in early legislative stages but represents a credible structural threat to pharmaceutical pricing power.
→ Revenues from Medicare Part B and Part D covered drugs would be repriced to the lowest global price; for blockbuster drugs with a US premium of 2-4x over international reference prices, per-unit revenue declines of 50-75% are implied for the Medicare population.
HR6319 is an early-stage bill that establishes a Lung Cancer Task Force within NIH to study research disparities, funding levels, and screenings. It authorizes no funding and creates no direct revenue or cost impact on any publicly traded company. No market action is justified at this stage.
HR4101 (Cancer Drug Parity Act) was introduced in the House and referred to committee in June 2025. It mandates equal cost-sharing for oral and intravenous anticancer drugs in group health plans. At this early legislative stage with no committee action or companion bill, the market impact is negligible. Targeted pharmaceutical companies with oral oncology portfolios could benefit if the bill advances, but passage is highly uncertain.
→ Lower patient cost-sharing for oral anticancer drugs increases patient adherence and prescription fill rates, expanding the addressable patient population for oral oncology products.
HR1990, the American Innovation and R&D Competitiveness Act, would restore immediate expensing for R&D costs, reversing the 2022 tax code change that required 5/15-year amortization. This is an early-stage bill referred to Ways and Means with 81 cosponsors, but if enacted, it would provide a direct 21% tax-rate cash flow benefit annually to every R&D-intensive US company. The largest absolute beneficiaries are mega-cap tech and pharma firms with $10B+ annual R&D budgets.
→ Reduction in taxable income by amount of annual R&D spend, improving after-tax cash flow by 21% of R&D expenses in year incurred
HR1931, the Access to Pediatric Technologies Act, is an early-stage House bill that would require CMS to establish Medicare payment methodologies for qualifying pediatric devices and drugs upon manufacturer request. The bill is referred to two committees with no further action in over a year. It authorizes no direct funding - it creates a regulatory pathway. For med-tech and pharma companies with pediatric product lines (JNJ, ABT, MRK, PFE), the bill is directionally positive but procedurally distant from becoming law.
→ Creates reimbursement certainty for pediatric drug manufacturers, reducing financial risk of developing pediatric indications for existing drugs or new pediatric formulations
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started →